Navigation Links
LifeStem International, Inc. Announces Increased Revenues, Decreased Operating Expenses
Date:5/14/2008

LAGUNA HILLS, Calif., May 14 /PRNewswire-FirstCall/ -- LifeStem International, Inc., (OTC Bulletin Board: LSTM), formerly CalbaTech, Inc., an emerging life sciences company concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions, as well as providing services in the collection, processing and storage of adult stem cells, today announced revenues for the first quarter of 2008 ending March 31 totaled $318,853, up from revenues of $311,970 in the same period in 2007.

The Company also announced that its gross profit increased to $195,260 in 2008 compared to $159,828 during the same period last year. "Significantly, we were able to decrease operating expenses twenty-four percent to $356,060 in the first quarter of 2008 compared to $471,922 last year," said James DeOlden, CEO. LifeSteam International announced a loss for the quarter due to adjustments for non-operating, non-cash derivates embedded in the Company's financing instrument.

"The therapeutic possibilities that may be provided by collecting and preserving healthy adult stem cells on a pre-disease basis may revolutionize the practice of medicine. The power and promise of stem cell therapies is just emerging, and the corresponding development of new clinical applications and therapies are expected to follow. LifeStem's Stem Cell Microbank(TM) Service focuses on refining existing collection processes that are gaining significant acceptance. The focus will be providing a stem cell collection process and storage service that maintains adult stem cells for future use and broadens the availability of a collection and storage service," Mr. DeOlden said. The Company's initial client collections through the Stem Cell Microbank(TM), originally scheduled for May 10, have been, at the clients' request, rescheduled for June 20.

About LifeStem International, Inc.

LifeStem International, Inc. (OTC Bulletin Board: LSTM) is the emerging life sciences company (http://www.lifesteminternational.com), concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions, as well as providing services in the collection, processing and storage of adult stem cells.

Note: Certain statements in this news release may contain "forward-looking" information within the meaning of rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Act of 1934 and are subject to the safe harbor created by those rules. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to being in a large and growing market, exhibiting rapid growth characteristics, and having a growth strategy, are forward looking statements. These forward looking statements are only predictions and are subject to certain risks, uncertainties and assumptions. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or assumptions in this press release include the risk that we will not be able to grow our revenues and market share, the risk that our prices do not remain competitive and the risk that we will not achieve profitability. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission, including our most recent Report on Form 10-KSB, and Reports on Form 10-QSB and Form 8-K. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims, any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.

Contact: Paul Knopick

E & E Communications

949/707-5365

pknopick@eandecommunications.com


'/>"/>
SOURCE LifeStem International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures
2. JPMorgans Principal Investment Management Group to Invest in Chindex International, Inc.
3. Corium International, Inc. Announces Appointment of Phyllis Gardner, M.D. and Daniel G. Welch to Board
4. China Pharma Holdings, Inc. Retains HC International, Inc. to Implement Investor Relations Program
5. Chindex International, Inc. to Present at 2008 UBS Global Healthcare Services Conference
6. Cryo-Cell International, Inc. Reports Results for Fiscal 2007
7. Bio-Clean International, Inc. to Present at Bluechip Capital Investment Forum
8. MINRAD International, Inc. Announces Appointment of David T. DiGiacinto as President and Chief Operating Officer
9. VWR International, LLC Acquires Jencons (Scientific) Ltd, UK
10. Sangui BioTech International, Inc., Reports Sales Increase, Continued Losses
11. Cryo-Cell International, Inc. Reports First Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)...  At the 2017 Health Information Management Systems ... , IBM (NYSE: IBM ) today introduced ... President and CEO Ginni Rometty will ... 8:30-10 am ET, broadcast live on www.ibm.com ... examine the advent of the Cognitive Era and ...
(Date:2/18/2017)... 2017 Kurzlehrgang mit Fokus ... Zelltherapie-Studien, Poster legt metaproteomische Analyse des Darm-Mikrobioms bei Säuglingen ... ... Dr. Yoav Peretz , Scientific Director bei ImmuneCarta, ... Assays zum Nachweis intrazellulärer Zytokine bei adoptiven Zelltherapie-Studien im ...
(Date:2/18/2017)... DUBLIN , Feb 17, 2017 Research ... Global Strategic Business Report" report to their offering. ... The report provides separate ... Europe , and Rest of World. Annual estimates and ... six-year historic analysis is provided for these markets. Market data and ...
(Date:2/17/2017)... 17, 2017  If only one in every ... mutation-conferring resistance to chemotherapy, thousands of cancer cells ... focused on finding these mutations in ever-smaller subpopulations ... tumor DNA in blood — to guide treatment ... Unfortunately, however, detecting these genetic anomalies may ...
Breaking Biology Technology:
(Date:1/26/2017)... Jan. 26, 2017  Acuity Market Intelligence today ... and Digital Identity".  Acuity characterizes 2017 as a ... increased adoption reflects a new understanding of the ... "Biometrics and digital identity are often perceived as ... Most , Principal of Acuity Market intelligence. "However, ...
(Date:1/24/2017)... , Jan. 24, 2017 Biopharm ... of the laboratory use of nuclear magnetic resonance ... experienced end-users and profiled current practices, developments, trends ... as well as growth and opportunities. These areas ... suppliers, NMR instruments, needs and innovation requirements, hyphenated ...
(Date:1/23/2017)... 2017  The latest mobile market research from Acuity ... dramatically. The quarterly average price of a biometric smartphone ... Q4 2016.  There are now 120 sub-$150 models on ... from just 28 a year ago at an average ... Maxine Most , Acuity Market Intelligence Principal, "Biometric Smartphones ...
Breaking Biology News(10 mins):